Amundi Asset Management US’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Amundi Asset Management US’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-117,758	Closed	-$14.6M	–	1583
2020 Q4	$14.6M	Sell	117,758 -7,076	-6%	-$930K	0.01%	720
2020 Q3	$12.2M	Sell	124,834 -3,584	-3%	-$448K	0.01%	683
2020 Q2	$20M	Sell	128,418 -10,379	-7%	-$1.58M	0.02%	509
2020 Q1	$20M	Sell	138,797 -3,593	-3%	-$694K	0.03%	403
2019 Q4	$29.1M	Sell	142,390 -43,801	-24%	-$7.99M	0.03%	449
2019 Q3	$14.9M	Buy	186,191 +2,272	+1%	+$193K	0.02%	600
2019 Q2	$17.4M	Buy	183,919 +49,814	+37%	+$4.3M	0.01%	629
2019 Q1	$11.5M	Buy	+134,105	New	+$11.1M	0.02%	677

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Amundi Asset Management US's RETA Position: Q1 2021 in Review

Amundi Asset Management US sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2021, closing a stake of 117,758 shares — an estimated $14.6M sold.

Amundi Asset Management US first reported a position in RETA in Q1 2019 and held it in 8 quarters. The position peaked at $29.1M in Q4 2019. 201 funds tracked by Wall St. Rank hold RETA as of Q1 2021.

Amundi Asset Management US reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
Amundi Asset Management US sold 117,758 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2021, an estimated $14.6M.
Amundi Asset Management US first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 8 quarters.
Amundi Asset Management US's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $29.1M in Q4 2019.
201 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.